Efficacy, safety and satisfaction of using emicizumab in hemophilia A patients without factor VIII inhibitors: A systematic review
Background: Hemophilia A is a genetic disorder characterized by deficiency or dysfunction of the factor VIII clotting protein, leading to serious bleeding disorders. Conventional treatment involves the exogenous administration of factor VIII. However, this therapy faces significant challenges, inclu...
Saved in:
| Main Authors: | Isabela de Oliveira Araujo, Lucas Fernandes Suassuna, Isabela Lima dos Santos, Daniela de Oliveira Werneck Rodrigues |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137925001178 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TSUBASA study: evaluation of the quality and content of daily life of people with hemophilia A without factor VIII inhibitors on prophylactic treatment with emicizumab
by: Teruhisa Fujii, et al.
Published: (2025-07-01) -
Real‐world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center
by: Qianqian Mao, et al.
Published: (2024-12-01) -
ERRATUM: Recommendations of Expert Group of Polish Society of Pediatric Oncology and Hematology on use of immune tolerance induction (ITI) in pediatric patients with hemophilia A complicated by a factor VIII inhibitor
by: Magdalena Wojdalska, et al.
Published: (2025-01-01) -
Thrombin generation to evaluate the complex hemostatic balance of hemophilia A plasma containing direct oral anticoagulant and supplemented by factor VIII
by: Sylvain Lamoine, et al.
Published: (2024-10-01) -
Prognostic factors for recurrence in acquired hemophilia A-results from a long-term observational study
by: Lisa Reich, et al.
Published: (2025-02-01)